A Phase IV Single Arm, Multicenter, Open-label Study Assessing Deep Molecular Response in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive CML in Chronic Phase After Two Years of Treatment With Nilotinib 300mg BID
Phase of Trial: Phase IV
Latest Information Update: 25 Jul 2017
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms NILOdeepR
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 26 Apr 2016 Planned End Date changed from 1 Dec 2019 to 1 Feb 2020.
- 26 Apr 2016 Planned primary completion date changed from 1 Dec 2019 to 1 Feb 2020.